Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1479-5876
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab ; volume:15 ; number:1 ; day:4 ; month:12 ; year:2017 ; pages:1-9 ; date:12.2017
Journal of translational medicine ; 15, Heft 1 (4.12.2017), 1-9, 12.2017
- Schlagwort
-
Krebs
Onkologie
- Urheber
-
Morello, Silvana
- Beteiligte Personen und Organisationen
-
Capone, Mariaelena
Sorrentino, Claudia
Giannarelli, Diana
Madonna, Gabriele
Mallardo, Domenico
Grimaldi, Antonio M.
Pinto, Aldo
Ascierto, Paolo Antonio
SpringerLink (Online service)
- DOI
-
10.1186/s12967-017-1348-8
- URN
-
urn:nbn:de:1111-201802037953
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Morello, Silvana
- Capone, Mariaelena
- Sorrentino, Claudia
- Giannarelli, Diana
- Madonna, Gabriele
- Mallardo, Domenico
- Grimaldi, Antonio M.
- Pinto, Aldo
- Ascierto, Paolo Antonio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Downregulation of CD73 associates with T cell exhaustion in AML patients
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
CD73 polymorphisms are associated with schizophrenia
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Soluble Fibrin Monomer Complexes in Patients with Renal Cell Carcinoma
Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Downregulation of CD73 associates with T cell exhaustion in AML patients
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
CD73 polymorphisms are associated with schizophrenia
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Soluble Fibrin Monomer Complexes in Patients with Renal Cell Carcinoma
Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
Downregulation of CD73 associates with T cell exhaustion in AML patients
Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma
CD73 polymorphisms are associated with schizophrenia
Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Soluble Fibrin Monomer Complexes in Patients with Renal Cell Carcinoma
Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events